GLYCO-IMMUNE CHECKPOINT INHIBITORS
Targeting Glycan-Sensing Checkpoints to Unleash Both the Innate and Adaptive Immune Responses to Cancer
GLYCO-IMMUNE CHECKPOINT INHIBITORS
Immuno-Oncology Today:
An Unmet Need
Despite the early success of first-generation immuno-oncology drugs, most cancer patients do not respond to these treatments or eventually develop resistance.
Our Science
Cell surface glycosylation is now known to play a central role in tumor immune evasion: Tumor cells evolve to express distinct immunosuppressive glycan patterns on their surfaces that down-regulate a wide spectrum of innate and adaptive immune cell types, which are critical for a coordinated anti-tumor immune response.
The Approach
Palleon Pharmaceuticals is the leading biotechnology company developing drugs to treat cancer by targeting glyco-immune checkpoints, which are glycan-sensing inhibitory receptors found on innate and adaptive immune cells.
News
Palleon Pharmaceuticals Announces Successful Defense of European Patent
November 26, 2018Palleon Pharmaceuticals Announces Preclinical Data from EAGLE Platform to be Presented at the AACR Special Conference on Tumor Immunology and Immunotherapy
Twitter
@Palleon_Pharma
This week is #WorldPharmaWeek and we look forward to discussing the highlights in #immunooncology from… http://Z9OnjfAEPK
@Palleon_Pharma
#DYK that every tumor has a unique glycan signature? By deciphering the tumor glyco-code, Palleon is working to mat… http://A58eHqMaeM